ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2089

Traction Therapy May Improve Hand Function in Those with Distal Interphalangeal Osteoarthritis

Grace Lo1, Lauren Drillock2, Kimberly Staines3, Michael Strayhorn4, Katherine Tse5, Gerald Virtanen6, Laura Welsh2, Monica Seu2, Eugene Gersh2, Ida Kristin Haugen7, Andrew Grainger8 and Jonathan Samuels9, 1Baylor College of Medicine / MEDVAMC, Houston, TX, 2NYU Langone Health, New York City, NY, 3MEDVAMC, Saltburn By The Sea, United Kingdom, 4Baylor College of Medicine, Houston, TX, 5NYU Langone Health, Brooklyn, NY, 6MEDVAMC, Houston, TX, 7Diakonhjemmet Hospital, Oslo, Norway, 8University of Cambridge, Cambridge, United Kingdom, 9NYU Langone, Rye Brook, NY

Meeting: ACR Convergence 2025

Keywords: functional status, hand, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2079–2105) Osteoarthritis – Clinical Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Hand osteoarthritis (OA) is the most common form of arthritis affecting the hand, but therapeutic options for OA at the distal interphalangeal (DIP) joint have limited efficacy. While the primary outcome of a randomized controlled clinical trial evaluating traction of the DIPs was null, we explored whether secondary outcome measures indicated a benefit of the treatment.

Methods: In this pilot multi-center, double-blind, controlled trial, of DIP hand OA in at least 3 joints, patients were randomized to a traction device (fig 1) along with standard of care vs standard of care. Patients were evaluated at baseline and at weeks 4, 12, and 24 for multiple measures of pain as well as functional assessments using questionnaires (the Disabilities of Arm Shoulder and Hand (DASH), the Michigan Hand Questionnaires, the Functional Index for Hand Osteoarthritis (FIHOA)) and clinical tests including the Functional Dexterity test, grip strength test, pinch strength test, and tenderness on joint palpation. All participants randomized into the study were included. We used a last observation carried forward strategy to address missing data.

Results: 33 participants were enrolled and randomized to either the experimental or control arm. Of the secondary outcome measures that we evaluated, two were statistically significant in when looking at the 24 week timepoints, these included the DASH and the Michigan Hand Outcome ADLs of both hands. The DASH scores were significantly better in the traction arm compared to the control by nearly 11 points (-10.9 (95% CI -21.8 – -0.2)), and the Michigan Hand Outcome ADLs of both hand scores were also better by 12.0 points (12.0 (1.1 – 22.8)). The 4 other functional hand outcomes, FIHOA, grip strength, AUSCAN function, and the Michigan Hand Outcome overall hand scores, did not meet statistical significance but all showed more improvement in the traction arm compared to the control arm. None of the pain outcome measures showed a signal for being more beneficial in either arm.

Conclusion: In our pilot RCT of finger traction for DIP hand OA, based on our secondary outcomes, there is a signal that function may be improved in the treatment arm. Our findings suggest that functional assessments might be a better outcome measure to evaluate treatment benefit for hand OA interventions compared to pain assessments. A larger clinical trial, perhaps with a focus on function instead of pain as an outcome, is warranted.

Supporting image 1

Supporting image 2


Disclosures: G. Lo: None; L. Drillock: None; K. Staines: None; M. Strayhorn: None; K. Tse: None; G. Virtanen: None; L. Welsh: None; M. Seu: None; E. Gersh: None; I. Haugen: None; A. Grainger: None; J. Samuels: None.

To cite this abstract in AMA style:

Lo G, Drillock L, Staines K, Strayhorn M, Tse K, Virtanen G, Welsh L, Seu M, Gersh E, Haugen I, Grainger A, Samuels J. Traction Therapy May Improve Hand Function in Those with Distal Interphalangeal Osteoarthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/traction-therapy-may-improve-hand-function-in-those-with-distal-interphalangeal-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/traction-therapy-may-improve-hand-function-in-those-with-distal-interphalangeal-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology